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Abstract
Rationale Identification of biomarkers that establish diag-
nosis or treatment response is critical to the advancement of
research and management of patients with depression.
Objective Our goal was to identify biomarkers that can
potentially assess fluoxetine response and risk to poor
treatment outcome.
Methods We measured behavior, gene expression, and the
levels of 36 neurobiochemical analytes across a panel of
genetically diverse mouse inbred lines after chronic
treatment with water or fluoxetine.
Results Glyoxylase 1 (GLO1) and guanine nucleotide-binding
protein 1 (GNB1) mostly account for baseline anxiety-like and
depressive-like behavior, indicating a common biological link
between depression and anxiety. Fluoxetine-induced biochem-
ical alterations discriminated positive responders, while base-
line neurobiochemical differences differentiated negative
responders (p<0.006). Results show that glial fibrillary acidic
protein, S100 beta protein, GLO1, and histone deacetylase 5
contributed most to fluoxetine response. These proteins are
linked within a cellular growth/proliferation pathway, suggest-
ing the involvement of cellular genesis in fluoxetine response.
Furthermore, a candidate genetic locus that associates with
baseline depressive-like behavior contains a gene that encodes
for cellular proliferation/adhesion molecule (Cadm1), support-
ing a genetic basis for the role of neuro/gliogenesis in
depression.
Conclusion We provided a comprehensive analysis of behav-
ioral, neurobiochemical, and transcriptome data across 30
mouse inbred strains that has not been accomplished before.
We identified biomarkers that influence fluoxetine response,
which, altogether, implicate the importance of cellulargenesis
in fluoxetine treatment. More broadly, this approach can be
used to assess a wide range of drug response phenotypes that
are challenging to address in human samples.
Keywords Depression.Anxiety.Fluoxetine.Genetic.
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Introduction
The social and economic burden of major depressive
disorder (MDD) is substantial. Despite the significant cost
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DOI 10.1007/s00213-011-2574-zassociated with depression, <30% of patients achieve
adequate response to a selective serotonin reuptake inhib-
itor (SSRI; Trivedi et al. 2006). There are several factors
that contribute to poor treatment outcome, including
gender, disease onset, and presence of comorbid psychiatric
disorders (Kornstein and Schneider 2001). Presently, the
therapeutic management of patients who relapse or fail to
respond is poorly defined. Partial responders or non-
remitters typically undergo a series of antidepressant
treatment modifications that are largely based on trial and
error, leading to delay in symptom resolution and treatment
discontinuation (Olfson et al. 2006; Warden et al. 2007). A
set of biomarkers that can prospectively identify patients
who will respond to a specific medication can provide an
evidence-based rationale for selecting an appropriate course
of antidepressant therapy.
Several large studies have been undertaken to identify
genetic biomarkers of antidepressant response (Garriock et
al. 2010; Ising et al. 2009; Uher et al. 2010). Pharmacoge-
netic studies of antidepressants in the Sequenced Treatment
Alternatives for Depression (STAR*D) trial have led to the
identification of genes associated with treatment response
(Hu et al. 2007; Kraft et al. 2007; Lekman et al. 2008;
McMahon et al. 2006; Paddock 2008), treatment resistance
(Perlis et al. 2008), and treatment-emergent suicidal
ideation (Laje et al. 2007, 2009; Perlis et al. 2007). In
addition, polymorphisms in genes that encode drug-
metabolizing enzymes and transporters have been tested
for correlation with treatment response (Peters et al. 2008).
Although several studies have yielded notable findings,
none meet the currently accepted standards in human
genetics for replication (Chanock et al. 2007).
The search for antidepressant biochemical markers is
complicated by multiple neurobiological abnormalities that
have been observed in depression, indicating that it is
unlikely for a single biological marker to characterize a
multifactorial disease like MDD. Many analytes, including
brain-derived neurotrophic factor (BDNF), serotonin trans-
porter, and monoamines, have been linked with depressive
symptoms and response to antidepressant therapy (Manji et
al. 2001; Nestler et al. 2002; Thase 2007). A few studies
have looked at biochemical markers that can be used as
diagnostic (Domenici et al. 2010; Jehn et al. 2006)o r
treatment markers (Ising et al. 2007; Schule et al. 2009) for
depression. Other physiologic markers including neuro-
structural and neurofunctional measures have shown prom-
ise as potential markers of antidepressant response
(Leuchter et al. 2009, 2010). It is yet to be determined
whether these biomarkers can prospectively predict re-
sponse prior to treatment.
A major limitation in evaluating the relationship between
antidepressant response and biochemical alterations in
human subjects is sample accessibility, whereby analysis
is typically restricted to human serum and postmortem
brain samples. The assessment of postmortem brain tissues
is limited by the inability to distinguish whether neuro-
biochemical abnormalities are causal or a consequence of
disease or treatment, while serum samples are more
accessible but provide a relatively myopic view of the
neurobehavioral mechanisms that occur in the brain.
Importantly, these limitations can be mitigated through the
use of inbred mouse strains, which are easily maintained
and manipulated for research purposes. Besides ease in
accessibility, mice within the same strain are homogeneous
at each genomic locus, which makes the identification of
genetic variants of drug response more feasible due to a
reduced genomic complexity.
In order to understand how biochemical and genetic
differences correlate with treatment response, we measured
depressive-like behavior, anxiety-like behavior, gene ex-
pression, and the levels of 36 neurobiochemical analytes
across a panel of genetically diverse mouse inbred lines
after chronic treatment with vehicle or fluoxetine. Neuro-
biochemical markers were chosen based on their putative
molecular function within pathways proposed to underlie
depression and anxiety, which include neuronal transmis-
sion, HPA axis regulation, and neuroimmune processes. To
our knowledge, this is the first study that simultaneously
measured and examined the role of 36 putative neuro-
biochemical markers across 30 mouse inbred strains. In this
study, we examined how baseline and treatment-induced
biochemical differences affect depressive-like and anxiety-
like responses. Our goal was to establish genetic and
biochemical biomarkers that can predict fluoxetine response
and to propose a molecular pathway that is critical in
mediating response to SSRIs. In addition, we examined
baseline neurobiological differences that affect depressive-
like and anxiety-like behaviors in an effort to identify
biomarkers that contribute to risk for poor treatment
outcomes.
Materials and methods
Animals
Thirty mouse inbred strains (129S1/SvImJ, A/J, AKR/J,
BALB/cJ, BTBRT<t>tf/J, BUB/BnJ, C3H/HeJ, C57BL/6J,
C57BLKS/J, C57BR/cdJ, C58/J, CBA/J, CE/J, DBA/2J,
FVB/NJ, I/LnJ, LG/J, LP/J, MA/MyJ, MRL/MpJ, NOD/
LtJ, NOR/LtJ, NZB/BlNJ, NZW/LacJ, P/J, PL/J, RIIIS/J,
SJL/J, SM/J, and SWR/J) aged 5–6 weeks were obtained
from The Jackson Laboratory (Bar Harbor, ME). Male
mice were housed four per cage in polycarbonate cages
on a 12-h light/dark cycle (lights on at 0700 hours) with
access to food and water ad libitum. Following 1 week
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treatmentgroup.Dependingoncost,availability,andestimated
intra-strain response variability, the number of animals treated
per treatment group ranged from 9 to 21 per strain. All
procedures were approved by the Institutional Animal Care
and Use Committee and followed the guidelines set forth by
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Drug treatment
Fluoxetine is a SSRI that has been extensively studied for
its effect on depressive behavior (Cipriani et al. 2005; Rossi
et al. 2004). Fluoxetine HCl was purchased from Spectrum
Chemicals (Gardena, CA). The mean water intake for each
strain was determined previously by measuring daily water
consumption for 3 weeks. This information, along with the
average weight measurements for each strain, was used to
determine the amount of fluoxetine required to provide a
daily oral dose of 0 or 18 mg/kg per mouse. A chronic
fluoxetine regimen of 18 mg/kg for 21 days was selected
based on the results of a previous dose–response study
which investigated the behavioral effects of fluoxetine
administration at 0, 5, 10, 14, or 18 mg/kg for 1, 6, or
21 days (Miller et al. 2008). In each strain, a comparison of
the mean daily water intake between vehicle- and
fluoxetine-treated animals indicates a minimal effect of
fluoxetine on water consumption (Electronic supplementary
material (ESM) Online Resource 1). Mice were treated
daily with fluoxetine or water throughout the end of the
study and were sacrificed 1 week after the open field test
between 1300 and 1600 hours.
Tail suspension test
Strains were randomly tested across day, time of testing,
and equipment. At any given time, only four to eight
animals per strain were tested. Each animal was tested only
once in each procedure. After chronic administration of 0 or
18 mg/kg of fluoxetine for 21 days, mice aged 9–10 weeks
were tested in a tail suspension apparatus (PHM-300 TST
Cubicle, Med Associates, St. Albans, VT) between 1300
and 1600 hours. In this test, the mouse is subjected to a
short-term inescapable stress by having its tail suspended.
Following failed attempts to escape, the mouse becomes
immobile, a response generally considered as behavioral
despair, a depressive-like behavior that is proposed to
model “hopelessness” (Steru et al. 1985, 1987). Immobility
was recorded for 7 min in 60-s blocks using the following
parameters: threshold=3, gain=8, and resolution=200 ms.
Since all strains were uniformly active for the first minute,
percent time spent immobile was calculated for the last
6 min of the test. This procedure has been used previously
to determine tail suspension test (TST) responses to
antidepressants (Fujishiro et al. 2002; Ukai et al. 1998).
Mice that climbed up their tail during testing were excluded
from analysis (number of animals excluded=104 out of 721
mice). Mean depressive-like behavior is reported in ESM
Online Resource 2.
Open field test
To minimize potential carryover effects between tests,
behavior in the open field was recorded a week
following TST. The open field (OF) test was conducted
between 1300 and 1600 hours using a 27.3×27.3-m open
field apparatus (MED-OFA-MS, Med Associates) which
was surrounded by infrared detection beams on the x-, y-,
and z-axes that automatically recorded the animals’
position and activity over the course of the experiment.
Activity in the open field was recorded for 10 min within
an environmental chamber that provided white noise (60–
64 dB) and low, indirect lighting (ESM Online Resource
2). The OF is commonly used to measure exploratory and
locomotive behavior in mice. This test exploits the
rodent’s innate aversion to well-lit open spaces. Based
on previous observations that showed increased explora-
tion toward illuminated open areas following the admin-
istration of anxiolytics (Choleris et al. 2001;C r a w l e y
1985), anxiety-like behavior was measured as percent time
spent in the center 25% of the open field. In addition,
locomotor activity was recorded by calculating the total
distance traveled in the open field. This behavior was
measured to assess whether general locomotor activity
confounded response in the TST.
Tissue collection
Upon completion of the study, mice were killed by cervical
dislocation and decapitation between 0900 and 1300 hours.
Trunk blood was quickly collected and allowed to clot on
ice. Following centrifugation, serum samples were collected
and stored at −20°C for the determination of fluoxetine and
norfluoxetine levels using liquid chromatography–tandem
mass spectrometry (LC-MS/MS). Micro-dissections of
individual regions were performed on serial coronal brain
sections that were placed on a cold metal block. The cortex
was taken from the same section for each animal and
immediately snap-frozen on dry ice and stored at −80°C for
gene expression and neurobiochemical analyses. Other
brain regions were used for RNA isolation and subsequent
gene expression analysis. Given that the neurobiochemical
markers we examined were primarily expressed in the brain
(Table 1), we measured the levels of these analytes in brain
tissue. Tissue size requirements limited brain transcriptome
analysis and neurobiochemical quantification to the cortex.
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A solution with 10 μL of serum and 150 μL of acetonitrile
w a ss p i k e dw i t h5μg/mL of each internal standard
(fluoxetine-D6 and norfluoxetine-D6). Following sample
filtration with a 0.45-μm filter plate, 50 μL of the filtrate
was diluted with 0.1% formic acid and injected into a Sciex
4000 LC-MS/MS (Sciex Inc., Concord, ON) equipped with
a Waters YMC Cyano HPLC column (2.0×23 mm,
Milford, MA). The mobile phase consisted of water/
acetonitrile/formic acid (75:25:0.1). A standard curve with
concentrations from 20 to 10, 000 ng/mL was used to
extrapolate the amounts of fluoxetine and norfluoxetine in
each sample (n=8–19 mice per strain per treatment group).
Table 1 List of neurobiochemical analytes simultaneously measured across multiple mouse inbred strains and their known functions
Biomarker Name Function GO category
ACTH Adrenocorticotropin-releasing hormone Neuroimmune (GO:0005179), (GO:0007218)
APOD Apolipoprotein D Neuroimmune (GO:0006629), (GO:0005215)
BAG1 BCL2-associated athanogene 1 Apoptosis (GO:0006916), (GO:0006950)
BDNF Brain-derived neurotrophic factor Neurogenesis (GO:0006916) (GO:0048167)
c-fos FBJ osteosarcoma oncogene Transcription (GO:0007399), (GO:0045941)
CREB cAMP response element-binding Signal Transduction (GO:0007165), (GO:0007202)
PPP1R1B Protein phosphatase 1 subunit 1B Modulation of phosphatase1 (GO:0007165), (GO:0004864)
DAT Dopamine transporter Regulation of dopamine levels (GO:0005329), (GO:0007268)
FKBP51 FK506-binding protein 51 Signal transduction (GO:0005528), (GO:0031072)
GAD67 Glutamic acid decarboxylase-67 Decarboxylation of glutamate
to GABA
(GO:0004351), (GO:0006915)
Galanin Galanin Neuronal modulation (GO:0005184), (GO:0006950)
GFAP Glial fibrillary acidic protein Maintenance of astrocytes (GO:0005200), (GO:0005882)
Ghrelin Ghrelin Neurotrophy and appetite
regulation
(GO:0006916), (GO:0008343)
GLO1 Glyoxylase1 Neuroprotection (GO:0006916), (GO:0006749)
GNB1 Guanine nucleotide-binding protein
subunit beta-1
Signal Transduction (GO:0006112), (GO:0007200)
GSK3β Glycogen synthase kinase 3 beta Phosphorylation (GO:0035255), (GO:0006916)
GSR Glutathione Reductase Neuroprotection (GO:0006749), (GO:0016491)
HDAC5 Histone deacetylase 5 Transcription (GO:0004407), (GO:0000122)
IL-6 Interleukin6 Neuroimmune (GO:0001781), (GO:0006954)
KCNJ9 Potassium inwardly rectifying channel,
subfamily J, member 9
Regulation of K
+ levels (GO:0015467), (GO:0006813)
MCH Melanin concentrating hormone Sleep and circadian rhythm (GO:0007218), (GO:0046005)
NET Norepinephrine transporter Regulation of norepinephrine
levels
(GO:0006836), (GO:0008504)
NGF Nerve growth factor Neuronal growth and signaling (GO:0008504), (GO:0006954)
NMDA1 Glutamate receptor, subunit 1 Neurotransmission (GO:0004972), (GO:0005234)
NPY Neuropeptide Y Neuropeptide signaling (GO:0005184), (GO:0001664)
NR3C1 Glucocorticoid receptor Neuroendocrine (GO:0004883), (GO:0006351)
NSG2 Neuron-specific family gene member 2 Dopamine receptor signaling
pathway
(GO:0007212), (GO:0050780)
P2X7 Purinergic receptor ligand-gated ion
channel 7
Regulation of Ca
2+ (GO:0010524), (GO:0000187)
PAQR8 Progestin and AdipoQ receptor 8 Steroid binding (GO:0004872), (GO:0005496)
PTH Parathyroid hormone Regulation of Ca
2+ (GO:0031856), (GO:0007186)
S100β S100 beta protein Glial cell proliferation (GO:0007417), (GO:0008283)
SERT Serotonin transporter Regulation of norepinephrine
levels
(GO:0008504), (GO:0015222)
SGNE Secretogranin V Neuroendocrine (GO:0016486), (GO:0007218)
TNF-α Tumor necrosis factor-alpha Neuroimmune (GO:0006955), (GO:0005125)
VEGF Vascular endothelial growth factor Growth and angiogenesis (GO:0001525), (GO:0005125)
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to-charge (m/z) ratios: m/z310→44 (fluoxetine), m/z296→
134 (norfluoxetine), m/z316→44 (fluoxetine-D6), and m/z
302→140 (norfluoxetine-D6). This information was used to
quantify serum fluoxetine and norfluoxetine levels (ESM
Online Resource 3).
Neurobiochemical analyte quantification
Prior to ELISA experiments, all antibodies were tested for
specificity by performing Western blot experiments in
pooled brain samples acquired from three mouse inbred
strains. Abundance of neurobiochemical markers was
measured using a parallelized reverse ELISA methodology
(Zeptosens—a division of Bayer (Schweiz) AG, Witterswil,
Switzerland). From each strain, cortex tissues were taken
from three animals in each treatment group and homoge-
nized in CLB1 buffer (Zeptosens) with zirconium oxide
beads for 30 s using QIAgen TissueLyser II (QIAgen,
Valencia, CA). Semi-solid brain tissues were mixed gently
on a tumbling shaker for 30 min at room temperature.
Following centrifugation (2 min at 10,000×g), supernatants
were transferred and stored at −80°C until further analysis.
The total protein concentrations for each sample were
determined using a modified Bradford assay (Coomassie
Protein Plus Assay, Pierce Biotechnology, Rockford, IL).
All samples were adjusted with CLB1 buffer to obtain a
uniform concentration of 2 mg/mL. Immediately after
dilution, each sample was spotted twice at concentrations
of 0.05, 0.10, 0.15, and 0.2 mg/mL of total protein.
Reference signals were obtained from simultaneous spot-
ting of assay buffer and labeled antibodies on the array
chip. Following overnight incubation with primary anti-
bodies, arrays were washed and incubated with
fluorescence-labeled anti-species secondary antibody for
2.5 h in the dark. Arrays were imaged simultaneously using
ZeptoREADER (Zeptosens) at excitation/emission wave-
lengths of 635/670 nm with exposure times of 0.3, 1, 5, and
10 s.
All images were analyzed using ZeptoVIEW 3.0
(version 3.0.1.17). Background intensities for each individ-
ual spot were determined by taking the mean signals of four
additional spots equidistant from the sample spot. Net
fluorescence intensities (NFI) were calculated by subtract-
ing the background signal from each sample spot signaling.
Following NFI determination, each NFI value was normal-
ized to the mean intensity of the reference spots. Using least
squares method, eight normalized NFI values obtained from
each sample were fitted linearly against tissue lysate protein
concentrations. The extrapolated signal intensity that
corresponds to the midpoint of the concentration range
(0.125 mg/mL) is defined as the reference fluorescence
intensity (RFI). Relative abundance for each neurobiochem-
ical marker was obtained by comparing inter-strain RFI
values. All neurobiochemical markers measured in this
study are listed in Table 1. The mean RFI scores for each
analyte are listed in ESM Online Resource 4. Behavioral,
neurobiochemical, and drug (fluoxetine and norfluoxetine)
concentration data for each animal were deposited at The
Jackson Laboratory Phenome Database (http://phenome.
jax.org/) under the name Wiltshire 2 and Wiltshire 3.
Statistical analysis
Response to treatment was calculated by taking the ratio of
fluoxetine behavioral scores to vehicle behavioral scores.
Percent change in immobility was calculated by multiplying
the ratio of fluoxetine immobility scores to vehicle
immobility scores by 100 and then subtracting the product
from 100. We defined positive and negative responders as
having at least 20% decreased or increased in immobility
scores, respectively. Given that the criterion was defined
subjectively, we also investigated the difference in response
using more stringent criteria, which were 30% and 40%
change in immobility scores. Strain and treatment effects on
immobility scores and percent time spent in the center of
the OF were obtained using a two-way analysis of variance.
Post hoc pairwise comparisons of behavioral scores
between control and fluoxetine groups were performed
using a Mann–Whitney U test. False discovery rate is
controlled at 0.10 using the Benjamini–Hochberg method.
Because both baseline neurobiochemical levels and
fluoxetine-induced biochemical alterations can affect the
SSRI response, we wanted to identify the relationship
between behavior and neurobiochemical alterations at
baseline and after fluoxetine treatment. Partial least squares
(PLS) regression analysis was used to extract latent vectors
that account for most of the covariance between biochem-
ical analytes and behavior in each treatment group. Once
the vector was extracted, we determined the biochemical
analytes that covary most with behavioral response by
assessing the PLS loading score for each analyte onto the
vector.
To identify biochemical markers that discriminate posi-
tive or negative responders, we used a distance weighted
discrimination (DWD) analysis. Unlike traditional multi-
variate analysis, this approach was intended for the analysis
of high dimension, low sample size data sets (Marron et al.
2007; Qiao et al. 2010). The DWD method was used to
identify a hyperplane that best distinguishes the positive or
the negative response groups. Following identification of a
DWD hyperplane, the DWD loading vector (orthonormal to
the hyperplane) was calculated, indicating the contribution
of each neurobiochemical marker in discriminating negative
or positive responders. The Direction Projection Permuta-
tion based hypothesis test (DiProPerm) with DWD was
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in each response group. In this procedure, the neurobiochem-
ical scores were projected onto the DWD vector and the two-
samplet statistic was computed. The t statistic obtained from
the real data set was compared with the t statistics obtained
from 1,000 relabeled group pairs with recomputed DWD
vector to determine whether the overall difference in neuro-
biochemical levels was significant (p<0.05).
We performed Pearson’s correlation analysis to determine
whether neurobiochemical levels correspond with the fluox-
etine, norfluoxetine, or mRNA expression levels. Molecular
connections between candidate treatment biomarkers were
evaluated using Ingenuity Pathway Analysis (IPA) software
(Ingenuity Systems, Inc. Redwood, CA). Statistical
analyses were performed using SAS 9.2 (SAS Institute,
Cary, NC), R Package version 2.13 (http://www.r-project.
org/), and MATLAB 7 (The MathWorks, Natwick, MA).
Transcriptome gene expression analysis
Brain regions were homogenized in 500 μL of Trizol using
a QIAgen TissueLyser at 30 Hz (QIAgen). The RNA for
each animal was isolated by guanidinium thiocyanate–
phenol–chloroform extraction and was further purified
using the RNAeasy miniprep kit (QIAgen) according to
the manufacturer’s directions. For each strain, RNA
samples for three animals in each treatment group were
pooled and converted to cDNA and biotinylated cRNA
(Enzo kit, Affymetrix, Santa Clara, CA). The resulting
cRNA was hybridized to Affymetrix GeneChip Mouse
Genome 430 2.0 arrays.
Following normalization with the gcRMA algorithm,
expression data were analyzed using ArrayAssist software
(Stratagene, La Jolla, CA). To identify genetic alterations
associated with fluoxetine administration and treatment
response, we analyzed the gene expression profiles between
the control and fluoxetine-treated mice as well as profiles
between negative and positive responders as defined by the
tail suspension phenotype. Microarray data were prepro-
cessed to identify genes with expression levels greater than
the background levels (intensity, >50). The gene expression
profiles for each treatment group (control vs. fluoxetine)
were filtered by calculating the fold change difference
between probes with minimum and maximum intensity
values. In each treatment group, genes that were significantly
variable between strains (fold change ≥3 between minimum
and maximum values) were analyzed. Alternatively, expres-
sion data between response groups (negative vs. positive)
were filtered by taking the ratio of fluorescence intensities
between fluoxetine and control mice within each strain. Probe
sets that were significantly affected by fluoxetine treatment
(intensity ratios of fluoxetine to vehicle ≥2 for at least one
strain) were selected. Following filtration, genes were
prioritized based on their signal-to-noise ratio (SNR), which
is the difference in median gene expression values divided by
the standard deviation. The p value for each observed SNR
was determined from the empirical null distribution of SNRs,
which was obtained by permuting the sample labels and
recalculating the SNRs 1,000 times (Gould et al. 2006).
Genes with a false discovery rate (FDR) of ≤0.05 were
considered significant.
S N Rr a n ks c o r e sw e r eu s e dt oi d e n t i f yg e n e st h a tw e r e
differentially expressed in either treatment (control vs.
fluoxetine) or response (negative vs. positive responders)
groups. These genes were then tested for their ability to
assign samples in each response or treatment category
using a k-nearest neighbors (k-NN) classification with a
leave-one-out cross-validationt e s tp r e v i o u s l yd e s c r i b e di n
Cover and Hart (1967) and Golub et al. (1999). Briefly,
the k-NN algorithm assigned a treatment or response label
on the unknown sample based on the class assignment
most frequently represented among its closest neighbors.
Class assignments were determined based on the expres-
sion profiles of genes deemed to be informative. The
validity of the model was tested using a leave-one-out
cross-validation test in which the algorithm withheld a
sample, built a class predictor model using the remaining
samples, and then predicted the class label of the withheld
test sample. Using a distance function, the model
determined which members of the training set were closest
to the test sample and then weighted each “vote”
according to the distance of the unknown test sample
from its neighbors, giving the closest neighbor the biggest
“vote.” This process was iteratively performed for each
sample and the cumulative error rate was calculated
(Cover and Hart 1967; Golub et al. 1999). An unsuper-
vised hierarchical clustering analysis was used to evaluate
the expression pattern of the informative genes for each
treatment and response group. Moreover, we performed
eQTL analysis on genes with significant SNR values
(FDR≤0.05) as described in Wu et al. (2008)t od e t e r m i n e
whether changes in gene expression following fluoxetine
treatment were under cis-regulation. Gene expression
analyses were performed using GenePattern 2.0 (Reich et
al. 2006) and R Package version 2.13. Gene expression
data were deposited into NCBI Gene Expression Omnibus
database (GSE28644).
A logistic regression analysis was used to identify
baseline genetic markers that can account for variable
fluoxetine response. Probe sets that were variable in the
control group (fold change ≥3 between minimum and
maximum values) were selected and evaluated for their
influence on fluoxetine response. By using these analyses,
we can identify baseline genetic markers that may be
predictive of SSRI response. Statistical analyses were
performed using R Package version 2.13.
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Efficient mixed-model association has been well described
elsewhere (Kang et al. 2008) and will be summarized here.
Experimental SNP genotypes encompassing over 500,000
polymorphic loci across 72 commonly used laboratory
strains were obtained from the Center for Genome Dynamics
at http://cgd.jax.org (Szatkiewicz et al. 2008;Y a n ge ta l .
2009). Over 190,000 SNPs were informative for the 30
mouse inbred lines, which provided the basis for inferring
the genotype. SNPs used in these analyses were fully
genotyped, not imputed, and had been specifically selected
to discriminate Mus musculus subspecies. This set of SNPs
avoids some of the previous biases in genome-wide analyses
and enables an accurate ascertainment of population sub-
structure. Associations between genotype and phenotype
were calculated by an F statistic corrected for population
structure and genetic relatedness. Results were plotted using
SpotFire software (TIBCO Palo Alto, CA). Genomic loci
that were associated with behavioral or biochemical pheno-
types at an FDR≤0.05 were considered significant.
Results
Behavioral measurements
Behavioralresponses weremeasured in the openfield testand
tail suspension test following chronic treatment with vehicle
(water) orfluoxetine.Analysisofimmobilityscoresacrossthe
30 mouse inbred strains revealed significant strain (F=29.83,
p<0.0001) and treatment (F=39.14, p<0.0001) as well as
significant strain by treatment effects (F=3.83, p<0.0001).
Similarly, significant strain (F=23.16, p<0.0001), treatment
(F=20.41, p<0.0001), and strain by treatment effects (F=
1.63, p<0.02) were observed for percent time spent in the
center of the OF. Compared with the control group, an
overall reduction in mean immobility was observed in mice
treated with fluoxetine (t=3.253, p<0.003). However,
change in immobility scores (fluoxetine response) was
variable between strains. Thirteen strains exhibited a 20%
reduction in immobility (positive responders), while five
inbred strains exhibited a 20% increase in immobility
(negative responders, Fig. 1). Post hoc pairwise comparisons
of the behavioral scores between treatment groups revealed a
significant difference in immobility scores for BALB/cByJ,
BUB/BnJ, C57BL/6J, C57BR/cdJ, CBA/J, MA/MyJ, P/J,
PL/J, and SM/J. Significant differences in anxiety-like
responses between vehicle- and fluoxetine-treated mice were
observed for DBA/2J, MA/MyJ, SJL/J, and SM/J (ESM
Online Resource 5).
Mean fluoxetine and norfluoxetine levels were variable
across the strains; concentration ranges are 470.3–
1274.8 ng/mL for fluoxetine and 578.6–1612.2 ng/mL for
norfluoxetine. No significant correlation was observed
between mean depressive-like behavior and mean serum
levels of fluoxetine (r
2=0.036) or its metabolite norfluox-
etine (r
2=0.047). This finding is similar to human studies
which did not find a significant association with antide-
pressant response and serum levels of fluoxetine or
norfluoxetine (Amsterdam et al. 1997; Beasley et al.
1990; Norman et al. 1993). With the exception of a few
markers, no significant correlation was detected between
neurobiochemical levels and drug concentration. Fluoxetine
level was minimally correlated with GSK3β (r
2=0.213),
histone deacetylase 5 (HDAC5, r
2=0.131), and vascular
endothelial growth factor (VEGF, r
2=0.155). A minimal
correlation between melanin concentrating hormone (MCH)
protein levels and norfluoxetine levels (r
2=0.135) was also
detected. There was no correlation between mean percent
immobility in the TST and total distance traveled in the OF
for control (r
2=0.013) and treated animals (r
2=0.083),
indicating that depressive-like behavior was not affected by
locomotor activity. We observed a modest correlation
between baseline and fluoxetine-induced immobility scores
(r
2=0.628), which suggests that baseline TST behavior is
linked with drug response. Genetic analysis can be performed
using inbred strain phenotype data to identify genetic loci
associated with behavioral phenotypes (Miller et al. 2010;
Williams et al. 2009). Independent QTL mapping analysis
for behavioral phenotypes identified significant loci for
anxiety, treatment response (data not shown), and baseline
behavioral despair. A locus on chromosome 9 (9: 46.7–
47.6 Mb) associated with baseline depressive-like behavior
(−logP=6.17, FDR≤0.059), and this was of particular
interest because of its co-localization with the genome-wide
association analysis for neurobiochemical markers.
Levels of S100β, GSK3β, HDAC5, and GFAP contribute
most to treatment response
The levels of 36 neurobiochemical markers proposed to be
involved in depression and anxiety were measured in the
cortex (Table 1). Dopamine transporter (DAT), interleukin-
6 (IL-6), FK506-binding protein 51 (FKBP51), glucocorti-
coid receptor (NR3C1), and neuron-specific family gene
member 2 (NSG2) were excluded from the analysis due to
weak intensities, irregular staining, or nonlinear dose–
response signals. We examined the relationship between
percent change in immobility and neurobiochemical levels.
The scatter plots show the strain distribution pattern for
each biochemical analyte against depressive-like responses
under vehicle (ESM Online Resource 6a) and fluoxetine
conditions (ESM Online Resource 6b). In the control
group, correlations between protein levels and mRNA
expression levels were detected for c-Fos (r
2=0.269,
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2=0.222,
1426508_at; r
2=0.184, 1426509_at; r
2=0.187,
1440142_s_at), glyoxylase 1 (GLO1; r
2=0.244, 1424108_at;
r
2=0.274, 1424109_a_at), and PAQR8 (r
2=0.1796,
1431042_at). In the fluoxetine group, correlations between
protein levels and mRNA expression levels were detected for
GFAP (r
2=0.183, 1440142_s_at; r
2=0.623, 1426508_at; r
2=
0.692, 1426509_s_at), guanine nucleotide-binding protein 1
(GNB1; r
2=0.144, 1454696_at; r
2=0.161, 1417432_at), and
NPY (r
2=0.154, 1419127_at). The lack of a strong correlation
between the neurobiochemical levels and corresponding
transcript levels indicates an indirect relationship between
mRNA and protein expression.
Partial least squares analysis of the data indicated that
the first vector accounted for 56% and 59% of the
covariance in neurobiochemical and behavioral differences
in the fluoxetine and control groups, respectively (ESM
Online Resource 7). Behaviors in the OF and TST
accounted for baseline behavior (PLS loading score onto
vector, 1; percent time spent in the center OF and
immobility TST, 75.1% and 56.4%, respectively). Howev-
er, the behavioral differences observed after chronic
fluoxetine treatment were mainly due to inter-strain
responses in the TST (PLS loading score onto vector, 1;
percent time spent in the center OF and immobility TST,
17.2% and 72.6%, respectively). Levels of GLO1 and
GNB1 account for most of the covariance in anxiety-like
and depressive-like behavior in the control group. Higher
levels of GLO1 and GNB1 associated with higher baseline
anxiety-like and depressive-like behavior. Alternatively,
Fig. 1 Inter-straindifferenceinfluoxetineresponse.Responsetotreatment
was calculated by taking the ratio of fluoxetine behavioral scores to vehicle
behavioral scores. Percent change in immobility was calculated by
multiplying the ratio of fluoxetine immobility scores to vehicle immobility
scores by 100 and then subtracting the product from 100. We defined
positive and negative responders as having at least 20% decreased or
increased in immobility scores, respectively. Immobility is a measure of
“hopelessness” or depressive-like behavior in mice. Strains with positive
response to fluoxetine exhibited significant reduction in depressive-like
behavior, while negative responders had an increased in immobility
304 Psychopharmacology (2012) 221:297–315fluoxetine-induced immobility behavior was mostly affect-
ed by GFAP, S100 beta protein (S100β), GLO1, and
HDAC5 (Fig. 2a). Lower immobility scores following
fluoxetine treatment were linked with higher levels of
GFAP, S100β, GLO1, and HDAC5.
In order to identify biomarkers of fluoxetine response,
we examined which biochemical analytes were most
effective in discriminating positive or negative responders.
An overall neurobiochemical difference was observed in
positive and negative responders. Neurobiochemical alter-
ations following fluoxetine treatment discriminate positive
responders, while baseline biological differences distin-
guish negative responders. This finding was observed
irrespective of the stringency in defining positive or
negative response, defined as 20–40% reduction or increase
in immobility, respectively (Fig. 2b). DWD analysis shows
that levels of S100β, GSK3β, HDAC5, GFAP, and GNB1
account for most of the variance in treatment response
(Fig. 2b). Baseline levels of S100β, GSK3β, HDAC5,
GFAP, and GNB1 can discriminate negative responders.
Chronic fluoxetine treatment affects these analytes, and the
levels of S100β, GSK3β, HDAC5, GFAP, and GNB1 post-
treatment indicate positive response to fluoxetine. The
direction of the vectors was the same for GSK3β and
HDAC5, but opposite for S100β a n dG N B 1w h e n
discriminating positive or negative responders. Negative
responders had lower levels of S100β and higher levels of
GNB1, HDAC5, and GSK3β at baseline, while positive
responders had lower levels of GNB1 and higher levels of
S100β, GSK3β, and HDAC5 after fluoxetine treatment
(Fig. 2b). GSK3β and HDAC5 can discriminate negative or
positive response, but have poor specificity in identifying
negative and positive response groups from each other,
while the opposing direction of the S100β and GNB1
vectors indicates that both analytes can discriminate
negative and positive response groups from each other.
Interestingly, we observed a minimal influence of GFAP on
positive response relative to its affect on negative response,
which suggests that elevation in GFAP is mainly indicative
of negative fluoxetine response.
In both analyses, the response to fluoxetine was
associated with an alteration in candidate neurobiochemical
levels (Fig. 2). Results from different methods of analysis
(PLS and DWD) show that levels of GFAP, S100β,
HDAC5, and GSK3β contribute to differential TST
responses after fluoxetine treatment. In order to address
whether fluoxetine mediates the levels of candidate treat-
ment markers S100β, GFAP, HDAC5, and GSK3β through
a common pathway, we looked for molecular connections
between them. Using IPA software, we discovered that all
candidate treatment markers are linked either directly or
indirectly. S100β, GFAP, HDAC5, and GSK3β connect
within a common cellular growth and proliferation network,
indicating the importance of cellular genesis in mediating
response to chronic fluoxetine treatment (ESM Online
Resource 8).
Gene expression profiles for treatment and response groups
Gene expression data collected from the cortex were
preprocessed to eliminate invariable probe sets, reducing
the number of probes from 45,101 to 4,818. From genome-
wide gene expression analysis, we first identified genes that
were strongly correlated with control or fluoxetine treat-
ment by computing the SNR ratio for 4,818 probe sets. We
found 203 probe sets that were differentially expressed in
either treatment group (FDR≤0.10). Based on the SNR
rank scores, 12 genes were significantly up-regulated in the
control or fluoxetine group, indicating that these genes are
likely to be informative for assigning treatment category
(ESM Online Resource 9a). To evaluate whether the
expression profiles of the informative genes can be used
to predict treatment classifications, we performed the k-NN
leave-one-out cross-validation test. The 12 informative
genes correctly predicted treatment class for 38 out of the
60 samples (absolute error of 36.6%), indicating that the
overall expression patterns of the informative genes do not
effectively predict treatment class. Because it is likely that
gene expression differences between vehicle- and
fluoxetine-treated mice may be confounded by inter-strain
difference in response, we then analyzed the gene expres-
sion profiles in the negative and positive response groups.
There were over 171 genes with variable expression
patterns in each response group (FDR≤0.05). Based on
the SNR rank scores, eight genes were significantly up-
regulated in either positive or negative responders, which
make them likely to be genetic predictors of fluoxetine
response (ESM Online Resource 9b). Using the k-NN
leave-one-out cross-validation algorithm, we tested to see
whether responders can be correctly assigned (negative or
positive) based on the expression patterns of the eight
informative genes. Sixteen out of the 18 samples were
correctly assigned to the appropriate response groups,
providing an absolute error rate of 11.1%. Results from
the regression analysis indicate that several baseline genetic
markers affect inter-strain variability in fluoxetine response
(ESM Online Resource 10). Using a previously described
eQTL analysis (Wu et al. 2008), we found that changes in
gene expression for the 171 genes were not likely due to
cis-regulation. Gene expression changes as measured by the
log ratios of fluorescence intensities (fluoxetine/vehicle) did
not significantly associate with polymorphic variants found
within 25–500 kb of the putative genes. A heat map was
generated following hierarchical clustering analysis where-
in the expression patterns of the informative genes were
used to cluster each treatment and response group (Fig. 3).
Psychopharmacology (2012) 221:297–315 305Fig. 2 a Neurobiochemicalmarkersthatcovarywithfluoxetineresponse
(top). PLS analysis show that levels of GNB1, GLO1, S100β, GAD67,
GFAP, and galanin covary most with response to open field and tail
suspension tests (white bars). Levels of GFAP, S100β, GLO1, HDAC5,
GAD67, P2X7, and GSK3β covary most with depressive-like response
following chronic fluoxetine treatment (black bars). b Neurobiochemical
analytes that contribute most to discriminating positive and negative
responders (bottom). DWD analysis shows that S100β, GSK3β,
HDAC5, and GNB1 discriminate positive responses (black bars)o r
negative response (white bars). The opposing direction of the S100β
and GNB1 vectors indicates that both markers can discriminate negative
and positive response groups from each other. Neurobiochemical
differences induced by chronic fluoxetine treatment discriminate positive
responders, while baseline neurobiological differences discriminate
negative responders. Overall, neurobiochemical difference is observed
when we defined positive response as a 20% (p<0.006), 30% (p<
0.014), or a 40% (p<0.026) reduction in immobility or when we defined
negative response as a 20% (p<0.006), 30% (p<0.036), or a 40% (p<
0.016) increase in immobility. Data are shown when response is defined
as 20% decreased or increased in immobility scores
306 Psychopharmacology (2012) 221:297–315Apart from a few specific strain divergences, the gene sets
indicateclusters oftreatment and responsegroups. Our results
show that gene expression differences were more apparent
betweenthe responsegroups(positive vs. negative) compared
with the treatment groups (control vs. fluoxetine), with the
gene set for the response groups being able to reasonably
predict SSRI response (Fig. 3).
Quantitative trait loci associated with baseline depressive-like
behavior and variable neurobiochemical levels
We alsoinvestigated whetherdifferencesinneurobiochemical
analytes, which have been previously linked to anxiety and/or
depression, are subject to a common genetic regulatory
mechanism. Of particular interest is that the convergence of
neurobiochemical and behavioral data revealed a significant
loci co-localization on Chr 9 (9: 46.7–47.6 Mb; Fig. 4). The
Chr 9 QTL associated with baseline depressive-like behavior
as well as baseline levels of cyclic AMP response element-
binding protein (CREB, −logP=4.46, FDR≤0.05) and
VEGF (−logP=5.56, FDR≤0.05). Genes at this locus
include Cadm1 and 2900052N01Rik. Cadm1 is involved in
the neural cell adhesion processes, facilitating cellular and
molecular communication between cells and has been linked
with social impairments and anxiety-like behavior in mice
(Takayanagi et al. 2010; Zhiling et al. 2008).
Discussion
Identification of biomarkers that can establish diagnosis,
prognosis, and response to treatment is critical to the
advancement of research and the management of patients
with mood disorder. Biomarkers can be used to objectively
assess clinical progression and response to antidepressant
therapy. Relative to human studies, the use of mouse inbred
strains can be an effective method for investigating
biomarkers of drug response due to lower cost, greater
tissue accessibility, reduced genomic complexity, and
subject availability. However, the use of animal models to
parallel subsets of behaviors that typify human disorders is
challenging, and many of the symptoms used to establish
psychiatric diagnoses in humans cannot be replicated in
animals (Nestler and Hyman 2010). Here, we assess limited
sets of specific behaviors that are relatively robust and have
been previously validated as responsive to antidepressive
drug treatment (Cryan et al. 2005; Kulkarni and Dhir 2007)
in a panel of genetically diverse inbred mouse strains (Liu
and Gershenfeld 2003; Ripoll et al. 2003; Trullas et al.
1989). The TST is primarily used to evaluate the antide-
pressant activity of novel compounds and does not itself
elicit depressive behavior; hence, evaluation of treatment
responses following exposure to chronic stress, an animal
model of clinical depression that has both face and
predictive validity (Nestler and Hyman 2010; Willner
1997, 2005), is needed for an independent validation of
treatment biomarkers.
Early studies from the STAR*D trial found a high co-
occurrence of anxiety and depression. Over 49% and 42%
of patients in the primary care and secondary care setting,
respectively exhibited “anxious depressive” symptoms
(Fava et al. 2006). Compared with patients with depression
alone, patients with comorbid anxiety and depressive
disorders are more likely to have prolonged, severe, and
recurrent symptoms (Andreescu et al. 2007; Fava et al.
2004) and are less responsive to treatment (Emmanuel et al.
1998; Fava et al. 2008). In this study, we examined how
baseline and treatment-induced biochemical differences
Fig. 3 a Hierarchical clustering of genes discriminating treatment
from control (left). Gene expression patterns of the 12 most
informative genes on each treatment group. b Hierarchical clustering
of genes discriminating positive and negative response to fluoxetine
treatment (right). Gene expression profiles of the eight most
informative genes on each response group. Only strains deemed to
have a response to treatment are shown. In both figures, color denotes
the direction of gene expression changes (red, up-regulated; blue,
down-regulated). Intensity illustrates the magnitude of change in gene
expression
Psychopharmacology (2012) 221:297–315 307affect depressive-like and anxiety-like responses. While
anxiety-like and depressive-like behavior both contribute to
baseline behavioral differences, anxiety-like behavior as
measured by percent time spent in the center of the OF was
only minimally affected by fluoxetine treatment. This result
supports previous findings which have demonstrated that
responses in the TST are more sensitive to antidepressant
drugs as opposed to other psychotropic agents like
anxiolytics, antipsychotics, and stimulants (Cryan et al.
2005). The levels of GLO1 and GNB1 mostly account for
anxiety-like and depressive-like behavior in the control
group, suggesting that alterations in GLO1 and GNB1 may
be common in both depression and anxiety disorders.
GLO1 is an antioxidant enzyme that catalyzes the detox-
ification of methylglyoxal and has been linked with various
psychiatric disorders including depression (Fujimoto et al.
2008), panic disorder without agoraphobia (Politi et al.
2006), schizophrenia (Arai et al. 2010), and anxiety-like
behavior (Hovatta et al. 2005; Williams et al. 2009).
Variable mRNA expression of Glo1 is likely due to the
difference in copy number variants. Duplication of a region
where Glo1 resides (Chr 17: 30.12–30.65 Mb) was found to
be associated with a difference in anxiety-like behavior
across a panel of mouse inbred strains (Williams et al.
2009). In agreement with a previous study that has found
higher Glo1 mRNA transcripts in more anxious mice
(Hovatta et al. 2005), we found that elevation in GLO1
protein corresponds with higher anxiety-like behavior.
Elevation in GLO1 protein is also correlated with increased
baseline immobility in the TST. This result is discordant
with other studies that have found higher expression of
GLO1 in less anxious and depressed mice (Ditzen et al.
2006; Kromer et al. 2005). Inconsistent findings may be
due to a number of factors including strain, age, and protein
quantification methodologies. Therefore, functional and
metabolic assessment of GLO1 through measurement of
methylglyoxal-mediated glycation is required for clarifica-
tion (Thornalley 2006). GNB1 belongs to a family of
heterotrimeric GTP-binding proteins that integrate signals
among receptors and effector proteins. In a study that
looked at dominant–subordinate behavior as a rodent model
of depression, lower mRNA expression of Gnb1 was
associated with dominant behavior (Kroes et al. 2006). In
agreement with this finding, we found that increased
behavioral despair is associated with higher GNB1 protein.
It is interesting to note that mice lacking Gnb1 exhibit
reduced cortical thickness, neural tube closure defects, and
impaired neural progenitor cell proliferation, suggesting the
importance of Gnb1 in neurogenesis (Okae and Iwakura
2010). Treatment with psychostimulants like cocaine and
amphetamines up-regulates Gnb1 expression, which indi-
cates that Gnb1 is involved in drug sensitization (Kitanaka
et al. 2002). Interestingly, pretreatment with fluoxetine
attenuates methamphetamine-induced locomotor sensitiza-
tion (Takamatsu et al. 2006), suggesting the potential
involvement of Gnb1 in fluoxetine response. Our results
Fig. 4 Genome-wide association plot for depressive-like behavior.
Genomic region on Chr. 9 significantly correlates with depressive-like
behavior (−logP=6.17) and baseline levels of VEGF (−logP=5.56)
and CREB (−logP=4.46). The figure shows baseline behavioral
despair QTL. To the right are the putative genes underneath
behavioral locus on Chr 9. The y-axis denotes the strength of
association between genotype and phenotype (−logP scores), and the
x-axis illustrates the cumulative SNP position on the genome
308 Psychopharmacology (2012) 221:297–315show that more anxious mice exhibit elevated levels of
GNB1 protein. A recent study by Benekareddy et al. (2010)
found that early stress induced by maternal separation up-
regulates Gnb1 expression, implicating the involvement of
Gnb1 in mediating risk to anxiety and mood disorder.
Taken together, the association of GLO1 and GNB1 with
baseline behavioral despair and anxiety-like behavior offers
a novel possibility in which these proteins can be targeted
to modulate both disorders and improve treatment out-
comes in patients who suffer from comorbid anxious
depressive symptoms.
To date, analysis of biochemical alterations has only
been performed for a handful of markers in a few inbred
strains despite inter-strain differences in response to
antidepressants (Crowley et al. 2006; Miller et al. 2008;
Ripoll et al. 2003; Vaugeois et al. 1997). In this study, we
show that response to fluoxetine treatment mirrors
responses seen in human fluoxetine treatment, with a subset
of strains exhibiting an “expected response” of reduced
immobility as a phenotype of depressive-like behavior.
Additionally, a few inbred strains exhibited no significant
response, while the remaining strains responded with
increased immobility. Similar to previous reports, we
observed a strong effect of strain and SSRI treatment on
TST responses (Crowley et al. 2006; Ripoll et al. 2003;
Trullas et al. 1989). Although the TST immobility scores
we measured after chronic fluoxetine treatment were
slightly different from what others have reported, our
findings are in agreement with a previous study that
examined TST responses in multiple inbred strains after
fluoxetine treatment (Lucki et al. 2001). Following acute
administration of fluoxetine, Lucki et al. (2001) observed
reduced immobility responses for BALB/cJ and DBA/2J,
but not for C57BL/6J, A/J, and C3H/HeJ. With the
exception of the data for C57BL/6J, these results are
consistent with our findings.
A low correlation was observed between change in
immobility scores (treatment response) and serum fluox-
etine and norfluoxetine levels, indicating that, at least in the
mouse, pharmacokinetics does not significantly modulate
behavior and that other factors like pharmacodynamics and
pharmacogenetics may contribute to differential responses
to fluoxetine treatment. Of note is that the negative and
positive responses to fluoxetine can be distinguished based
on neurobiochemical variability. Baseline biological differ-
ences discriminate negative responders, while biochemical
alterations following fluoxetine treatment delineate positive
responders. This result suggests that a positive response to
fluoxetine is mostly due to treatment-induced biochemical
alterations and that a negative response to fluoxetine is
mainly attributed to baseline differences between mouse
strains. Therefore, we propose that patients who fail to
respond or remit from antidepressant therapy may have
baseline biological abnormalities predisposing them to poor
therapeutic outcomes.
Overall, we found minimal correlation between mRNA
expression and protein levels for a small number of
neurobiomolecules. The lack of correlation between protein
abundance and mRNA expression levels can be due to
variable posttranscriptional and posttranslational mecha-
nisms, different protein synthesis and turnover rates, and
high degree of noise in mRNA and protein experiments
(Greenbaum et al. 2003). To date, correlation analysis
between transcript levels and protein abundance has been
performed in a few studies (Anderson and Seilhamer 1997;
Chen et al. 2002; Guo et al. 2008; Gygi et al. 1999; Ideker
et al. 2001; Pascal et al. 2008; Washburn et al. 2001). In
general, these studies found a weak correlation between
protein levels and mRNA expression levels, which suggests
that protein abundance cannot be sufficiently predicted by
mRNA expression data alone. The relationship between
transcript levels and its corresponding protein levels are
affected by transcription, translation, and regulatory pro-
cesses within the cell. Given that proteins are more directly
linked to the phenotype than mRNA transcripts, protein
data are likely to be more useful for characterizing the
molecular basis of disease. However, due to the limited
ability to comprehensively measure protein levels, global
profiling analysis is currently restricted to mRNA expres-
sion studies. It is important to note that both transcriptome
and protein abundance data provide useful information for
disease modeling and pathway analysis. Gene expression
and protein abundance data can be used to predict protein–
protein interactions (Greenbaum et al. 2003), which can
provide insight into the mechanisms underlying the disease.
Results from both DWD and PLS analyses suggest that
levels of S100β, GSK3β, HDAC5, and GFAP influence
differential TST responses following SSRI treatment
(Fig. 2). Chronic fluoxetine treatment results in higher
levels of S100β, which triggers the expression of serotonin
transporters (SERT) and activates de novo serotonin
synthesis (Baudry et al. 2010). Similarly, increased levels
of GSK3β have been observed following chronic fluox-
etine administration in vivo (Fatemi et al. 2009; Li et al.
2004). Inhibition of GSK3β blocked the fluoxetine-
mediated down-regulation of SERT through the over-
expression of miR 16 (Baudry et al. 2010), thus linking
serotonin regulation with GSK3β phosphorylation (Li et al.
2004). Tsankova et al. (2006) found that treatment with
tricyclic antidepressants results in lower mRNA levels of
Hdac5 and that overexpression of Hdac5 in the hippocam-
pus blocks the antidepressant effects of imipramine in the
chronic social defeat stress paradigm. Consistent with
previous studies (Baudry et al. 2010), higher levels of
S100β following fluoxetine treatment were observed in
positive responders. Interestingly, both negative and posi-
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HDAC5. GSK3β phosphorylates various molecules typically
leading to substrate inhibition, while chromatin remodeling by
HDAC5 can prevent the transcription of many downstream
genes. Thus, elevation of GSK3β and HDAC5 can affect
several different downstream molecular processes, leading to
variable treatmentoutcomes. Additionalstudiesarerequired to
examine the relationship between fluoxetine response and
levels of GSK3β and HDAC5. We found minimal correlation
between fluoxetine concentrations and GSK3β (r
2=0.213)
and HDAC5 (r
2=0.131) protein levels. This result suggests
that in comparison to S100β and GNB1, GSK3β and
HDAC5 levels are more sensitive to fluoxetine treatment.
The minimum correlation observed suggests that the affects
of GSK3β and HDAC5 on fluoxetine response may partially
be influenced by fluoxetine levels. Little information is
known about the relationship of GFAP with fluoxetine
response. In rodents, chronic treatment with fluoxetine results
in the elevation of amplifying neural progenitor cells (Encinas
et al. 2006), while antidepressant treatment in humans results
in the increased numbers of quiescent neural progenitor cells,
including nestin and GFAP (Boldrini et al. 2009). Rat
astrocytic cells enriched with GFAP exhibit Na
+-dependent
and fluoxetine-sensitive serotonin uptake, suggesting the
involvement of GFAP in mediating serotonin levels (Dave
and Kimelberg 1994). The underlying mechanism mediating
the influence of GFAP on negative fluoxetine response
warrants closer examination, given the low clinical response
rates to SSRI treatment (Trivedi et al. 2006).
Although our findings indicate that fluoxetine adminis-
tration alters the levels of S100β, HDAC5, GSK3β, and
GFAP, it is likely that these biochemical changes are not
specific to SSRIs. Other psychotropic medications, including
clozapine, lithium, valproic acid, and haloperidol, have been
shown to alter GFAP (Fatemi et al. 2008) and GSK3β levels
(Fatemi et al. 2009) in vivo. Altered levels of S100β are
observed in patients with schizophrenia (Gattaz et al. 2000;
Wiesmann et al. 1999), which can be normalized by
treatment with antipsychotic agents (Ling et al. 2007; Steiner
et al. 2010). Treatment with HDAC inhibitors is associated
with neuroprotective effects and may be beneficial in the
treatment of various psychiatric disorders, including bipolar
disorder and schizophrenia (Kazantsev and Thompson 2008;
Tsankova et al. 2007). Collectively, these findings suggest
that S100β,G S K 3 β, HDAC5, and GFAP are likely to be
involved in a behavioral pathway common to multiple
psychiatric disorders, although the downstream mechanisms
mediated by each analyte may be specific for each
psychiatric disorder. An important avenue for future study
is the assessment of these biomarkers in easily accessible
samples like plasma or serum, thus facilitating translation of
preclinical findings to human studies. Current work in the
lab aims to evaluate the relationship between behavioral
responses and serum levels of neurobiochemical markers
across multiple inbred strains. Additionally, sex differences
in the metabolism of fluoxetine (Hodes et al. 2010)
necessitate further investigation of these biomarkers in
females.
Overall, we observed minimal difference (203 probe sets
with variable expression patterns) in gene expression
profiles between vehicle- and fluoxetine-treated mice. This
result is consistent with what others have found when
performing global transcriptome analyses between control
and antidepressant treatment groups (Bohm et al. 2006; Lee
et al. 2010; Miller et al. 2008; Takahashi et al. 2006).
Although other groups have found more genes that were
up- or down-regulated following fluoxetine treatment, the
filtering criteria we used to preprocess our microarray data
are generally more stringent in comparison. We only
analyzed genes with a minimum threefold difference in
expression between strains and had statistically significant
SNR values. In addition, other factors including fluoxetine
dosing regimen, microarray methodology, and time of
tissue collection can influence gene expression results.
When we compared the gene expression profiles between
negative and positive responders, we found that we can
accurately assign samples as either negative or positive
responders (absolute error rate, 11.1%) based on the
expression patterns of Copg2S2, Prcp, Gpr115, Gxylt2,
Plb1, Txndc9, Mum1/1, and Gm1642, making these genes
potential predictors of SSRI response. Although none of
these genes have been directly linked to antidepressant
response or major depressive disorder, several are involved
in molecular processes that may be critical in mediating
behavior or neuronal function, such as neuropeptide
signaling and lysosomal serine carboxypeptidase activity.
For six of the genetic markers of fluoxetine response, there
are commercially available ELISA kits and antibodies that
can be used to evaluate the relationship between protein
levels of these genes and SSRI response. Additionally, we
identified baseline genetic markers that affect inter-strain
despair responses to fluoxetine treatment, suggesting use as
potential prognostic treatment biomarkers. Interestingly,
one candidate gene is a poly(A)-binding protein, cytoplas-
mic 1 (Pabpc1), a gene that was significantly associated
with SSRI response in a genome-wide association study
which evaluated over 1,800 patients from the STAR*D trial
(Shyn et al. 2011). Pabpc1 encodes for a poly(A)-binding
protein that binds to the poly(A) tail of mRNA, facilitating
ribosome recruitment and translation initiation. Given that
the association between Pabpc1 and antidepressant re-
sponse was observed in both preclinical and human studies,
the mechanism underlying this association warrants further
investigation.
To identify genetic markers for depressive disorder, we
focused on genomic regions that are associated with both
310 Psychopharmacology (2012) 221:297–315behavioral and neurobiochemical phenotypes. We identified
a behavioral despair QTL on Chr 9 that correlated with
inter-strain neurobiochemical variability. A QTL for
depressive-like behavior has not been reported previously
at this locus, which contains only two genes—Cadm1 and
2900052N01Rik. Cadm1 encodes for neural cell adhesion
molecules that mediate cell-to-cell communication. Further-
more, Cadm1 is involved in synaptic function and neuronal
differentiation (Watabe et al. 2003) and has been linked
with anxiety-like and social behavior in mice (Takayanagi
et al. 2010; Zhiling et al. 2008). A recent study by
Takayanagi et al. (2010) showed that mice lacking Cadm1
displayed higher anxiety-like phenotype and impairment in
motor coordination and social behavior compared to wild-
type mice. However, no significant difference in depressive-
like behavior as measured by the TSTwas observed between
groups (Takayanagi et al. 2010). Other behavioral paradigms
like chronic social defeat stress and reduced sucrose
preference, which assess other features of depressive
behavior (e.g., anhedonia; Nestler and Hyman 2010)c a nb e
used to further evaluate the role of Cadm1 in depression.
Since CADM1 acts as a synaptic adhesive molecule,
functional disruption of Cadm1 may lead to impaired neural
plasticity and neurogenesis, both of which have been linked
with major depressive disorder (Campbell and Macqueen
2004; Schmidt and Duman 2007). Links defining interac-
tions between Cadm1 and the two biochemical markers
(CREB and VEGF) that co-localize to the same genetic locus
on Chr 9 provide a promising avenue for future study.
Altogether, our results highlight the role of cellular
proliferation in mediating SSRI response. Similar to
Cadm1, Gpr115, Plb1, Gxylt2, and Prcp are involved in
cellular proliferation and/or cellular adhesion (Bjarnadottir
et al. 2004; Ganendren et al. 2006; Mallela et al. 2008,
2009; Okajima et al. 2008; Sethi et al. 2010). Furthermore,
candidate fluoxetine markers S100β, GSK3β, HDAC5, and
GFAP are linked through a common cellular growth and
proliferation pathway, suggesting that treatment with
fluoxetine stimulates cell growth. Our results indicate that
response to fluoxetine is affected by cellular genesis, which is
consistentwith previousstudiesthathaveshown a criticalrole
of neurogenesis in mediating SSRI response (Deltheil et al.
2009; Manev et al. 2001). Regulation of neurogenesis,
cellular resilience, neuroplasticity, and cellular death/atrophy
is important in the pathogenesis and treatment of depression
(Duman 2002; Krishnan and Nestler 2008;L u c a s s e ne ta l .
2010; Manji et al. 2001, 2003). Neuroimaging and postmor-
tem brain studies show that patients with MDD have
impaired neural circuitry and structural abnormalities. Com-
pared with healthy controls, patients with mood disorder
display lower number of glial cells, reduced cortical volume
and thickness, and decreased neuronal size and density, all of
which implicate cellular atrophy/loss (Manji et al. 2001,
2003). Antidepressant therapy increases the levels of
neurotrophic factors (Duman et al. 2001; Malberg et al.
2000;S a i r a n e ne ta l .2005) that promote neurogenesis and
inhibit cell death signaling pathways (Riccio et al. 1999).
Hippocampal neurogenesis is critical in facilitating adap-
t i v er e s p o n s et os t r e s s( D u m a ne ta l .2001; Malberg et al.
2000), memorydevelopment(Mirescuetal.2004; Schloesser
et al. 2009), and learning new experiences (Kempermann
2008); thus, the impairment of neurogenesis may confer risk
to depressive behavior. Elucidating the roles of neurogenesis,
cellular resilience, neural plasticity, and cell death in the
development of depressive behavior requires a system-level
exploration of these processes. Whether the interplay
between cellular proliferative and survival processes facili-
tates synaptic remodeling and leads to altered mood remains
to be seen.
In the absence of biological markers, therapeutic out-
comes are defined based on the reduction of baseline
symptoms, which can lead to inconsistencies and irrepro-
ducibility. Genetic and neurobiochemical markers can
provide an objective means to measure prognosis and
treatment response. We identified genetic and biochemical
markers of fluoxetine response that are involved in cellular
genesis, highlighting the role of neurogenesis and neuro-
plasticity in major depressive disorder. Since neurogenesis
is not specific to antidepressant treatment, it is critical for
future studies to identify how psychotropic medications
differentially affect neurogenesis and which downstream
neurobiological pathways are affected. Such studies may
illuminate differences between closely related psychiatric
disorders including depression and anxiety.
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